Iffath Ahmed, HamdanIftikhar Siddiqui, GhaniaShehzad Qureshi & GrisildaVidya Bernhardt. (2022) A review of literature on the pharmacogenomics of single-nucleotide polymorphisms. Biomedical and Biotechnology Research Journal (BBRJ) 6:1, pages 14.
Crossref
Azher Arafah, Shafat Ali, Sabhiya Majid, Samia Rashid, Shabhat Rasool, Hilal Ahmad Wani, Iyman Rasool & Muneeb U. Rehman. 2021. Genetic Polymorphism and cancer susceptibility. Genetic Polymorphism and cancer susceptibility
23
52
.
Marina Borro, Andrea Botticelli, Federica Mazzuca, Elisa Concetta Onesti, Giovanna Gentile, Adriana Romiti, Bruna Cerbelli, Eva Mazzotti, Luca Marchetti, Luana Lionetto, Maurizio Simmaco & Paolo Marchetti. (2016) Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget 8:8, pages 14050-14057.
Crossref
G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti & M Borro. (2015) Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. The Pharmacogenomics Journal 16:4, pages 320-325.
Crossref
A. Ducournau, P. Lagarde, B. Henriques de Figueiredo, M. Antoine, C. Breton-Callu, A. Petit, B. Dallaudière & P. Sargos. (2014) Radiothérapie chez une patiente atteinte d’un cancer du sein et d’ostéogenèse imparfaite : à propos d’un cas. Cancer/Radiothérapie 18:2, pages 132-135.
Crossref
Miriam López-Gómez, Paloma Cejas, María Merino, David Fernández-Luengas, Enrique Casado & Jaime Feliu. (2012) Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?. Clinical and Translational Oncology 14:9, pages 641-658.
Crossref
Soma Ghosh, M. Zulfiquer Hossain, Michael Borges, Michael G. Goggins, Roxann G. Ingersoll, James R. Eshleman, Alison P. Klein & Scott E. Kern. (2012) Analysis of Polymorphisms and Haplotype Structure of the Human Thymidylate Synthase Genetic Region: A Tool for Pharmacogenetic Studies. PLoS ONE 7:4, pages e34426.
Crossref
K. F. Newton, W. Newman & J. Hill. (2012) Review of biomarkers in colorectal cancer. Colorectal Disease 14:1, pages 3-17.
Crossref
C.S. Boskos, C. Liacos, D. Korkolis, K. Aygerinos, I. Lamproglou, E. Terpos, E. Stoupa, G. Baltatzis, K. Beroukas, P. Papasavvas, M.A. Dimopoulos & A. Bamias. (2010) Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. Journal of Surgical Oncology 102:5, pages 408-412.
Crossref
Takayuki Shibata, Shin-ya Kawasaki, Jun-ya Fujita, Tsutomu Kabashima & Masaaki Kai. (2010) A novel and specific fluorescence reaction for uracil. Analytica Chimica Acta 674:2, pages 234-238.
Crossref
Roberta Ferraldeschi. 2010. Pharmacogenetics: Making cancer treatment safer and more effective. Pharmacogenetics: Making cancer treatment safer and more effective
61
86
.
Jonathan R. Brody, Tomas Hucl, Christina L. Costantino, James R. Eshleman, Eike Gallmeier, Heng Zhu, Michiel S. van der Heijden, Jordan M. Winter, Agnieszka K. Wikiewicz, Charles J. Yeo & Scott E. Kern. (2009)
Limits to Thymidylate Synthase and
TP53
Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence
. Cancer Research 69:3, pages 984-991.
Crossref
Joseph Ciccolini, Cédric Mercier & Gérard Milano. 2009. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
249
265
.
E. Casado, J. De Castro, C. Belda-Iniesta, P. Cejas, J. Feliu, M. Sereno & M. González-Barón. (2007) Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clinical and Translational Oncology 9:9, pages 549-554.
Crossref
Daniel B Longley, Wendy L. Allen & Patrick G. Johnston. (2006) Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:2, pages 184-196.
Crossref
Cédric Mercier & Joseph Ciccolini. (2006) Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy. Clinical Colorectal Cancer 6:4, pages 288-296.
Crossref
Sharon J. Gardiner & Evan J. Begg. (2006) Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacological Reviews 58:3, pages 521-590.
Crossref
Wei Peng Yong, Federico Innocenti & Mark J. Ratain. (2006) The role of pharmacogenetics in cancer therapeutics. British Journal of Clinical Pharmacology 62:1, pages 35-46.
Crossref
Su-arpa Ploylearmsaeng, Uwe Fuhr & Alexander Jetter. (2006) How may Anticancer Chemotherapy with Fluorouracil be Individualised?. Clinical Pharmacokinetics 45:6, pages 567-592.
Crossref
Makoto INADA, Takefumi SHIMIZU & Nobuhiro IKEI. (2006) Determination of Dihydropyrimidine Dehydrogenase Activity in Human Peripheral Blood Mononuclear Cells by Radio-HPLC Method. BUNSEKI KAGAKU 55:1, pages 45-49.
Crossref
Suminobu Ito, Takeshi Kawamura, Makoto Inada, Yoshiharu Inoue, Yukihiro Hirao, Toshihisa Koga, Jun‐ichi Kunizaki, Takefumi Shimizu & Hitoshi Sato. (2005)
Physiologically based pharmacokinetic modelling of the three‐step metabolism of pyrimidine using
13
C‐uracil as an
in vivo
probe
. British Journal of Clinical Pharmacology 60:6, pages 584-593.
Crossref
Makoto Inada, Yukihiro Hirao, Toshihisa Koga, Minoru Itose, Jun-ichi Kunizaki, Takefumi Shimizu & Hitoshi Sato. (2005)
RELATIONSHIPS AMONG PLASMA [2-
13
C]URACIL CONCENTRATIONS, BREATH
13
CO
2
EXPIRATION, AND DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY IN THE LIVER IN NORMAL AND DPD-DEFICIENT DOGS
. Drug Metabolism and Disposition 33:3, pages 381-387.
Crossref
Mika Endo, Masanori Miwa, Hiroyuki Eda, Masako Ura, Hiromi Tanimura, Tohru Ishikawa, Taeko Miyazaki-Nose, Kazuo Hattori, Nobuo Shimma, Hisafumi Yamada-Okabe & Hideo Ishitsuka. (2003) Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. International Journal of Cancer 106:5, pages 799-805.
Crossref
Daniel B. Longley, Ultan McDermott & Patrick G. Johnston. (2003) Predictive Markers for Colorectal Cancer: Current Status and Future Prospects. Clinical Colorectal Cancer 2:4, pages 223-230.
Crossref
D B Longley, U McDermott & P G Johnston. (2002) Clinical significance of prognostic and predictive markers in colorectal cancer. The Pharmacogenomics Journal 2:4, pages 209-216.
Crossref
Sharon J. Gardiner, Evan J. Begg & Bridget A. Robinson. (2012) The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil. Adverse Drug Reactions and Toxicological Reviews 21:1-2, pages 1-16.
Crossref
Naoko Takebe, Shi-Cheng Zhao, Ali U Ural, Martin R Johnson, Debabrata Banerjee, Robert B Diasio & Joseph R Bertino. (2001) Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Therapy 8:12, pages 966-973.
Crossref
Syma Iqbal & Heinz-Josef Lenz. (2001) Determinants of prognosis and response to therapy in colorectal cancer. Current Oncology Reports 3:2, pages 102-108.
Crossref
John G Kuhn. (2016) Fluorouracil and the New Oral Fluorinated Pyrimidines. Annals of Pharmacotherapy 35:2, pages 217-227.
Crossref
Federico Innocenti, Lalitha Iyer & Mark J. Ratain. (2000) Pharmacogenetics. Clinical Pharmacokinetics 39:5, pages 315-325.
Crossref
Masami Asai, Satoshi Sumi, Kiyoshi Kidouchi, Hiromi Imaeda, Hajime Togari & Yoshiro Wada. (2000) Urinary pyrimidine analysis in healthy newborns, infants, children, adults and patients with congenital metabolic diseases. Pediatrics International 42:5, pages 499-503.
Crossref
Tohru Maeda, Satoshi Sumi, Katsuo Hayashi, Kiyoshi Kidouchi, Tadashi Owaki, Hajime Togari, Shinji Fujimoto & Yoshiro Wada. (1999) Automated determination of 5-fluorouracil and its metabolite in urine by high-performance liquid chromatography with column switching. Journal of Chromatography B: Biomedical Sciences and Applications 731:2, pages 267-273.
Crossref
A B P Van Kuilenburg, H van Lenthe, M J Blom, E P J Mul & A H Van Gennip. (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. British Journal of Cancer 79:3-4, pages 620-626.
Crossref
L. Iyer & M.J. Ratain. (1998) Pharmacogenetics and cancer chemotherapy. European Journal of Cancer 34:10, pages 1493-1499.
Crossref
A.B.P. Van Kuilenburg, P. Vreken, L.V.A.M. Beex, R. Meinsma, H. Van Lenthe, R.A. De Abreu & A.H. Van Gennip. (1997) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. European Journal of Cancer 33:13, pages 2258-2264.
Crossref
Martin R. Johnson, Jieming Yan, Lingning Shao, Nicolas Albin & Robert B. Diasio. (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography B: Biomedical Sciences and Applications 696:2, pages 183-191.
Crossref
Corey J. Langer. (2012) Dihydropyrimidine Dehydrogenase Deficiency: A Potential Etiology for 5‐Fluorouracil‐Induced Neurotoxicity—Author's Reply. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17:4, pages 849-849.
Crossref
P. Beuzeboc, J.-Y. Pierga, D. Stoppa-Lyonnet, M.C. Etienne, G. Milano & P. Fouillait. (1996) Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. European Journal of Cancer 32:2, pages 369-370.
Crossref
Zhihong Lu, Ruiwen Zhang & Robert B. Diasio. (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*. Clinical Pharmacology & Therapeutics 58:5, pages 512-522.
Crossref
Satoshi Sumi, Kiyoshi Kidouchi, Satoru Ohba & Yoshiro Wada. (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 672:2, pages 233-239.
Crossref
R. MEINSMA, P. FERNANDEZ-SALGUERO, A.B.P. VAN KUILENBURG, A.H. VAN GENNIP & F.J. GONZALEZ. (1995) Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea. DNA and Cell Biology 14:1, pages 1-6.
Crossref
R. B. Diasio, A. B. P. Van Kuilenburg, Z. Lu, R. Zhang, H. Van Lenthe, H. D. Bakker & A. H. Van Gennip. 1994. Purine and Pyrimidine Metabolism in Man VIII. Purine and Pyrimidine Metabolism in Man VIII
7
10
.
Robert B. Diasio, Zhihong Lu, Ruiwen Zhang & Harout S. Shahinian. 1995. Concepts, Mechanisms, and New Targets for Chemotherapy. Concepts, Mechanisms, and New Targets for Chemotherapy
71
93
.
H. Yokota, P. Fernandez-Salguero, H. Furuya, K. Lin, O.W. McBride, B. Podschun, K.D. Schnackerz & F.J. Gonzalez. (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.. Journal of Biological Chemistry 269:37, pages 23192-23196.
Crossref